A strong launch pipeline for 2022-23 (FY23), market share gains, and cost-control efforts are expected to drive strong revenue and earnings growth over the next two years for the country's fourth-largest pharmaceutical (pharma) company by market capitalisation (m-cap), Dr. Reddy's Laboratories.
While the company's bottom line grew 10.5 per cent annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over the next two years, observes ICICI Securities.
The January-March quarter (fourth quarter, or Q4) performance in FY22 and growth in the current financial year (FY23) are the near-term triggers. Double-digit price erosion notwithstanding, the company's US business registered 7 per cent growth on a sequential basis to $265 million, beating analyst estimates.
The US is the largest geography for the company and accounted for 37 per cent of consolidated sales in Q4FY22. The performance of its peers (barring Cipla at 7 per cent quarter-on-quarter, or QoQ, growth to $161 million) in the US market was weaker.
Lupin reported 10.4 per cent decline sequentially to $181 million, on the back of product recalls and price erosion.
Zydus Lifesciences (formerly Cadila Healthcare), too, reported a decline (minus 5 per cent) on a sequential basis to $189 million due to competitive pricing.
This story is from the May 23, 2022 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the May 23, 2022 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Over 282 Mn Faced Acute Hunger In 2023: UN
Gaza had the largest number of people facing famine
Meta Projects Weak Revenue Amid Ai Push
Facebook parent reported 27% revenue rise in first quarter
Hyundai Set To Drive In Five EVs By 2030
Hyundai Motor India will introduce five new electric vehicles (EVs) by 2030, said the South Korean automaker on Thursday, bringing forward its "locally tailored" plans for the sector by two years.
Blinken Tells China To Manage Ties 'Responsibly' As Talks Begin
US Secretary of State Antony Blinken on Thursday called on China to provide a level playing field for American businesses as he began a visit aimed at resolving a raft of contentious issues that could jeopardise the newly repaired relationship.
Axis Bank rerating to continue on steady NIM
The bullish stance on the lender comes after its outperformance in March quarter
After Bitcoin's massive price surge, book partial profit if overexposed
At current elevated prices, prospective buyers should opt for staggered purchases
Gradual volume recovery, valuations to support HUL sto
Hindustan Unilever's (HUL'S) performance for the quarter ended March 2023 (Q4FY24) was in line with modest consensus expectations.
Kotak Mahindra Bank's loan, deposit growth may be impacted: Analysts
Kotak Mahindra Bank's loan and deposit growth are likely to be affected after the Reserve Bank of India (RBI) asked the private-sector lender not to take on board new customers through the bank's online and mobile banking channels and not to issue any new credit cards, according to analysts.
Mkts gain for 5th session on the trot
Rising for the fifth straight session, equity benchmark Sensex rallied nearly 500 points to reclaim the 74,000 mark, while the Nifty closed above the 22,550 level on Thursday due to heavy buying in banking, financial and metal stocks.
Bank actively working to address RBI's concerns: CEO
A day after the severe action by the Reserve Bank of India (RBI), Kotak Mahindra Bank's Chief Executive Officer and Managing Director Ashok Vaswani on Thursday said the lender is \"actively working\" to address the concerns raised by the regulator.
